Stocktoria

Alector, Inc. ALEC

Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2019-02-07
Chart by TradingView
1/9
Piotroski F — financial health
-9.85
Altman Z″ — distress risk · distress
Dividend payout · no dividend

Financials & ratios (annual, from 10-K)

MetricFY2025FY2024FY2023FY2022FY2021
Financials
Revenue$21.0M$100.6M$97.1M$133.6M$207.1M
Operating income-$156.0M-$145.0M-$151.7M-$137.8M-$37.4M
Net income-$142.9M-$119.0M-$130.4M-$133.3M-$36.3M
Operating cash flow-$184.0M-$229.9M-$184.2M-$20.3M$298.6M
Free cash flow-$184.1M-$231.2M-$186.5M-$24.4M$295.3M
Total assets$293.2M$468.3M$621.8M$787.6M$814.7M
Total liabilities$262.6M$341.5M$487.7M$573.2M$513.9M
Shareholders' equity$30.6M$126.8M$134.2M$214.4M$300.7M
Ratios
Operating margin-741.3%-144.2%-156.3%-103.2%-18.0%
Net margin-679.2%-118.4%-134.3%-99.8%-17.5%
FCF margin-874.7%-229.9%-192.2%-18.3%142.6%
Return on assets-48.7%-25.4%-21.0%-16.9%-4.5%
Return on equity-466.3%-93.9%-97.2%-62.2%-12.1%
Debt / equity0.30×0.07×0.00×
Current ratio3.833.403.187.745.37
Revenue growth-79.1%3.6%-27.4%-35.5%881.5%

Notable holders (13F)

InvestorSharesValue
RENAISSANCE TECHNOLOGIES LLC1,287,691$2.8M
Point72 Asset Management, L.P.80,091$172,196

Why these scores methodology →

Piotroski F-score: 1/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: -9.85 (distress)

  • Working capital / assets 0.672
  • Retained earnings / assets -3.315
  • EBIT / assets -0.532
  • Equity / liabilities 0.117

Sector peers

VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →

Source: SEC EDGAR filings · CIK 0001653087 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.